Actinium Pharmaceuticals, Inc. (ATNM) — 10-K Filings
All 10-K filings from Actinium Pharmaceuticals, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Actinium Eyes Blockbuster Radiotherapy Market with Differentiated Pipeline
— Mar 30, 2026 Risk: high
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company focused on targeted radiotherapies, reporting a market value of voting stock -
Actinium Pharmaceuticals Files 2024 Annual Report
— Mar 31, 2025 Risk: low
Actinium Pharmaceuticals, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware and headq -
Actinium Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K
— Mar 29, 2024 Risk: low
Actinium Pharmaceuticals, Inc. (ATNM) filed a Annual Report (10-K) with the SEC on March 29, 2024. Actinium Pharmaceuticals, Inc. filed its annual report on For
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX